Direct and indirect regulation of the tumor immune microenvironment by VEGF

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding

(2021) Evripidis Lanitis et al.   Journal for ImmunoTherapy of Cancer

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

(2021) Yuqing Zhang et al.   JCI Insight

Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment

(2020) Naoki Horikawa et al.   BRITISH JOURNAL OF CANCER

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

(2020) Rong En Tay et al.   CANCER GENE THERAPY

Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia

(2020) Patricia E. de Almeida et al.   Cancer Immunology Research

VEGFR1+ metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome

(2019) Aida Freire Valls et al.   CLINICAL CANCER RESEARCH

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

(2019) A.Y. Shah et al.   EUROPEAN JOURNAL OF CANCER

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

(2019) Breelyn A Wilky et al.   LANCET ONCOLOGY

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

(2019) Hannah Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

Vascular regulation of antitumor immunity

(2019) Lance L. Munn et al.   SCIENCE

Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma

(2019) Yu Long et al.   CANCER RESEARCH

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

(2019) Mariangela Di Tacchio et al.   Cancer Immunology Research

VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models

(2019) Johannes Riegler et al.   NEOPLASIA

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

(2019) Joyce F. Liu et al.   JAMA Oncology

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

(2019) Chang Gon Kim et al.   Science Immunology

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

(2019) Xuyao Zhang et al.   Journal for ImmunoTherapy of Cancer

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

(2018) Heinz Läubli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy

(2018) Raimund Bauer et al.   CANCER RESEARCH

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

(2018) Xiaolei Li et al.   Cellular & Molecular Immunology

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

(2018) Michael B Atkins et al.   LANCET ONCOLOGY

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

(2018) Janos L. Tanyi et al.   Science Translational Medicine

Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer

(2018) Wen-kun Bai et al.   OncoTargets and Therapy

Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours

(2018) Adama Sidibe et al.   Nature Communications

Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells

(2018) Toshiki Iwai et al.   Oncotarget

The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes

(2018) Paulina Krzyszczyk et al.   Frontiers in Physiology

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

(2018) Adriana Albini et al.   Frontiers in Immunology

The Dual Nature of Type I and Type II Interferons

(2018) Amanda J. Lee et al.   Frontiers in Immunology

Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma

(2018) Courtney S. Malo et al.   Frontiers in Oncology

Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer

(2018) Yuqing Zhang et al.   MOLECULAR CANCER RESEARCH

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

(2018) Yasuko Tada et al.   Journal for ImmunoTherapy of Cancer

Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

(2017) Chun-Jung Chang et al.   INTERNATIONAL JOURNAL OF CANCER

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma

(2017) Yujie Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

STING, DCs and the link between innate and adaptive tumor immunity

(2017) Ralph E. Vatner et al.   MOLECULAR IMMUNOLOGY

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy

(2017) B A Castro et al.   ONCOGENE

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

(2017) M. Wroblewski et al.   Nature Communications

Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade

(2017) Chiara Secondini et al.   OncoImmunology

1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

(2017) J.F. Vansteenkiste et al.   ANNALS OF ONCOLOGY

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma

(2016) Alissa A. Thomas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

(2016) Stephanie Du Four et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

(2016) Naoki Horikawa et al.   CLINICAL CANCER RESEARCH

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation

(2016) Nougboli A. E. Oussa et al.   JOURNAL OF IMMUNOLOGY

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer

(2016) Filippos Koinis et al.   Journal of Thoracic Oncology

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

(2016) Brian I Rini et al.   LANCET ONCOLOGY

Molecular control of activation and priming in macrophages

(2016) Christopher K Glass et al.   NATURE IMMUNOLOGY

Mechanisms and regulation of endothelial VEGF receptor signalling

(2016) Michael Simons et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

(2016) Teresa E. Peterson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

(2016) Jonas Kloepper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer

(2016) Hai Hu et al.   TUMOR BIOLOGY

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

(2016) X. Wu et al.   Cancer Immunology Research

Vaccination approach to anti-angiogenic treatment of cancer

(2015) Madelon Q. Wentink et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation

(2015) Hua Huang et al.   FASEB JOURNAL

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis

(2015) Bin-Zhi Qian et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interferons and the Immunogenic Effects of Cancer Therapy

(2015) Andy J. Minn   TRENDS IN IMMUNOLOGY

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

(2015) Virgil E.J.C. Schijns et al.   VACCINE

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

(2015) Stephanie Du Four et al.   OncoImmunology

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

(2015) Oana Draghiciu et al.   OncoImmunology

Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells

(2015) Svetlana Karakhanova et al.   OncoImmunology

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function

(2015) Annkristin Heine et al.   PLoS One

Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes

(2015) Konrad Gabrusiewicz et al.   Oncotarget

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature

(2014) John G. Facciponte et al.   JOURNAL OF CLINICAL INVESTIGATION

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells

(2014) HAIYAN WANG et al.   Experimental and Therapeutic Medicine

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis

(2014) Vladimir Riabov et al.   Frontiers in Physiology

Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity

(2013) Andrea Casazza et al.   CANCER CELL

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

(2013) Fumitaka Arihara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice

(2013) D. Chinnasamy et al.   CANCER RESEARCH

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

(2013) J. Xu et al.   CANCER RESEARCH

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Increased circulating Lin−/lowCD33+HLA-DR−myeloid-derived suppressor cells in hepatocellular carcinoma patients

(2013) Peng Shen et al.   HEPATOLOGY RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms

(2013) Brady L. Stein et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

(2013) Leilei Tao et al.   MEDICAL ONCOLOGY

The miR-126–VEGFR2 axis controls the innate response to pathogen-associated nucleic acids

(2013) Judith Agudo et al.   NATURE IMMUNOLOGY

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer

(2013) Lana E. Kandalaft et al.   OncoImmunology

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

The Pancreas Cancer Microenvironment

(2012) C. Feig et al.   CLINICAL CANCER RESEARCH

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases

(2012) M. Shibuya   JOURNAL OF BIOCHEMISTRY

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signal transduction by vascular endothelial growth factor receptors

(2011) Sina Koch et al.   BIOCHEMICAL JOURNAL

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

(2011) P. Allavena et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

(2011) Apostolos C. Ziogas et al.   INTERNATIONAL JOURNAL OF CANCER

Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions

(2010) S. B. Coffelt et al.   CANCER RESEARCH

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor

(2010) Ilaria Marigo et al.   IMMUNITY

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells

(2010) Tom T. Chen et al.   JOURNAL OF CELL BIOLOGY

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis

(2010) S. Mocellin et al.   JNCI-Journal of the National Cancer Institute

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction

(2010) Laura A. Sullivan et al.   PLoS One

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

(2009) C Alfaro et al.   BRITISH JOURNAL OF CANCER

Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer

(2009) P.-Y. Pan et al.   CANCER RESEARCH

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

(2009) C. L. Roland et al.   MOLECULAR CANCER THERAPEUTICS

VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment

(2008) Masato Murakami et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells

(2008) F. Shojaei et al.   CANCER RESEARCH

Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice

(2008) S. P. Dineen et al.   CANCER RESEARCH

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

(2008) H. van Cruijsen et al.   CLINICAL CANCER RESEARCH

Novel functions of the CD34 family

(2008) J. S. Nielsen et al.   JOURNAL OF CELL SCIENCE

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

(2008) Maciej Kujawski et al.   JOURNAL OF CLINICAL INVESTIGATION

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

(2008) Christian Stockmann et al.   NATURE